Iovance Shows Unprecedented Amtagvi Response Rates, Analysts Uphold $9 and $10 Targets
On February 5 Iovance Biotherapeutics presented real-world retrospective study results showing unprecedented response rates for its one-time T cell therapy Amtagvi in advanced melanoma patients. On February 6 H.C. Wainwright reiterated its Buy rating with a $9 price target and on February 4 Barclays kept an Overweight rating at $10.
1. New Amtagvi Data
Iovance Biotherapeutics unveiled retrospective real-world clinical data demonstrating unprecedented response rates for Amtagvi in patients with advanced melanoma. The study evaluated outcomes in patients whose tumors could not be removed surgically or had metastasized, highlighting stronger efficacy than previously reported in earlier trials.
2. Analyst Ratings Maintained
Following the data release, H.C. Wainwright on February 6 reaffirmed a Buy rating with a $9 price target, reflecting confidence in commercial uptake. Earlier on February 4, Barclays maintained its Overweight stance with a $10 target, citing the robust profile of the therapy.
3. Amtagvi Product Profile
Amtagvi is the first one-time tumor-infiltrating lymphocyte (TIL) therapy approved for a solid tumor indication and is the only FDA-approved treatment for advanced melanoma patients post–anti-PD-1 and targeted therapy. Its commercial launch marks a significant step in adopting personalized cell therapies for oncology.